Recent share performance and business snapshot
iRhythm Holdings (IRTC) has offered a mixed ride for shareholders recently, with the stock down about 31% year to date and about 12% over the past year, but still up about 63% over five years.
Over shorter periods, the share price fell about 3% over the past day, gained about 1% over the past week, rose about 5% over the past month, and declined about 21% over the past 3 months, highlighting shifting sentiment around the stock.
The company reports revenue of US$787.851 million from its global ambulatory cardiac monitoring business, all currently generated in the United States, while posting a net loss of US$27.784 million, which keeps profitability in focus for investors.
See our latest analysis for iRhythm Holdings.
At a share price of US$120.66, iRhythm’s recent 1 month share price return of about 4.7% contrasts with its year to date share price decline of about 31%. However, the 5 year total shareholder return of about 63% shows how long term holders have still come out ahead.
If you are comparing iRhythm with other healthcare technology opportunities, it can be useful to see which peers are attracting attention in AI powered medical tools, starting with 34 healthcare AI stocks
With shares down so far this year despite revenue growth and a market value of about US$4.0b, the key question is whether iRhythm is undervalued today or if the current price already reflects its future growth potential.
Most Popular Narrative: 38.1% Undervalued
iRhythm's most followed narrative pegs fair value at $195 per share, well above the recent close at $120.66. This sets up a valuation story built around growth and future profitability.
The growing push towards population health management, preventative care, and value-based reimbursement is aligning directly with Zio's evidence-supported, scalable monitoring platform, supporting both recurring usage and improved payer coverage, which should drive higher revenues and improved net margins over time.
Curious what kind of revenue trajectory, margin uplift, and future earnings power are baked into that target? The full narrative lays out a detailed financial road map underpinning the $195 fair value call.
Result: Fair Value of $195 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, DOJ related investigations and ongoing regulatory remediation, alongside sector wide pressure on valuation multiples, could quickly challenge the current undervalued narrative if sentiment turns.
Find out about the key risks to this iRhythm Holdings narrative.
Another way to look at iRhythm’s valuation
The earlier fair value of $195 per share comes from a narrative model. By contrast, Simply Wall St’s fair ratio work with P/S points to a different story. With iRhythm trading around 5x sales versus a fair ratio of 3.9x and a peer average near 3.8x, the multiple already reflects a lot of optimism. If the market eventually moves closer to that fair ratio, it is worth asking how much conviction you really have in the growth and margin profile that would support staying at 5x.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Does this mix of caution and opportunity match how you view iRhythm right now? Take a closer look at both sides of the story with 4 key rewards and 1 important warning sign
Looking for more investment ideas?
Before moving on, take a moment to line up a few fresh ideas that could round out your watchlist and help you compare iRhythm with other opportunities.
- Target potential mispricings by scanning companies that combine quality fundamentals with attractive price tags using the 49 high quality undervalued stocks.
- Strengthen your portfolio's foundations by focusing on businesses with healthy finances through the solid balance sheet and fundamentals stocks screener (44 results).
- Get ahead of the crowd by tracking lesser known opportunities with robust metrics using the screener containing 21 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com